Will Buffett’s 23-Quarter Streak Start Again?
For more than half a decade, Warren Buffett’s Berkshire Hathaway accumulated the same stock quarter after quarter, 23 straight times, to be exact. Then, without warning, the buying stopped last year.
It wasn’t because Buffett lost faith in the company. In fact, his recent moves suggest he’s been biding his time, waiting for the numbers and the price to line up again.
» Read more about: Will Buffett’s 23-Quarter Streak Start Again? »
Read More
Is Shopify a Slam Dunk Buy on the Dip?
Recently, an under-the-radar tech company has captured the interest of top-tier investment funds. Hedge funds have quietly been acquiring significant shares that displays a conviction in this company’s potential to redefine its market.
So, what’s the stock is it a buy on the dip?
Key Points
- Shopify’s shift beyond subscriptions to financial services,
» Read more about: Is Shopify a Slam Dunk Buy on the Dip? »
Read More
1 Titan Health Stock Is Way Too Cheap
Merck & Co. (NYSE: MRK) might be best known for its drugs like Keytruda and Gardasil, but those blockbusters haven’t been enough to get shareholders excited as the share price has fallen under water this year, down 6%.
It may well be a pharmaceutical powerhouse but recent price weakness suggests that Merck may be flying under the radar for investors,
» Read more about: 1 Titan Health Stock Is Way Too Cheap »
Read More
Paul Tudor Jones Is Betting Big Against the Bond Market: How You Can Too.
Stan Druckenmiller and Paul Tudor Jones, both among the most successful traders ever, are now on the same side of a trade: shorting long-duration bonds.
This move is more than just a hedge but rather it’s a bet that interest rates are headed higher, and when these legendary traders make such strong statements,
» Read more about: Paul Tudor Jones Is Betting Big Against the Bond Market: How You Can Too. »
Read More
Is Ambiq the Answer to AI’s Biggest Blind Spot?
AI might be the future, but that future has a power problem. For all the fanfare surrounding generative AI, one inconvenient truth continues to lurk in the background, which is it consumes an extraordinary amount of energy.
And unless someone cracks the code on power efficiency, scaling AI beyond the data center and into billions of edge devices will remain an expensive dream.
» Read more about: Is Ambiq the Answer to AI’s Biggest Blind Spot? »
Read MoreThe Burst
Buffett’s Final Chapter Begins
On May 3, Warren Buffett made headlines with the announcement that he will officially step down as CEO of Berkshire Hathaway at the end of 2025—a position he’s held since 1965. That’s a 60-year reign marked by one of the greatest investing track records in history. Under Buffett’s watch, Berkshire compounded returns at an astonishing 19.9% annually.
» Read more about: Buffett’s Final Chapter Begins »
Read MoreThe Spotlight
1 Seriously Overlooked Healthcare Stock That Could Soar
Sometimes the seemingly most boring companies in the world produced the most extraordinary returns. One healthcare firm that hasn’t shot up – yet – but which has attracted the attention of a multi-billion dollar fund with a pristine track record may be set to do so.
Better yet, it’s trading close to the estimated price paid by the fund,
» Read more about: 1 Seriously Overlooked Healthcare Stock That Could Soar »
Read MoreThe Daily
TSLA: Tesla Stock Slides as Robotaxi Autonomy Faces Scrutiny
This article first appeared on GuruFocus.
Tesla (NASDAQ:TSLA) shares slipped about 1% on Friday morning after questions emerged over the autonomy of its Austin robotaxis.
The company recently claimed the vehicles operate without a safety monitor onboard.
» Read more about: TSLA: Tesla Stock Slides as Robotaxi Autonomy Faces Scrutiny »